New drug combination before surgery for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new combination of two medicines (SHR-A2102 and adebrelimab) given before surgery to treat early-stage triple-negative breast cancer. This approach aims to shrink the tumor and potentially improve the chances of a cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer is triple-negative (tests negative for estrogen, progesterone, and HER2 receptors) and PD-L1 positive, meaning it has a protein that may help it grow.
- Your tumor is early-stage, meaning it has not spread to other parts of your body (only in the breast and possibly nearby lymph nodes).
- You have not had any previous treatment for breast cancer, such as chemotherapy, radiation, or surgery.
- You are generally in good health, able to perform daily activities, and have adequate heart, liver, kidney, and blood function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests a combination of two drugs given before surgery for early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink tumors and improve outcomes while possibly reducing the need for more intensive treatment.
This trial tests a combination of two targeted medicines given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can improve outcomes for patients with this type of breast cancer.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial tests a new combination of two targeted drugs given before surgery to shrink HER2-positive breast cancer. It may help make surgery more successful and reduce the chance of the cancer coming back.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.